Design Therapeutics hints at ‘strategic realignment,’ replaces CEO; Karyopharm co-founder leads ATP's Nereid

17 Nov 2023

Executive ChangeAcquisitionIPO

→ Design Therapeutics chairman Pratik Shah has succeeded João Siffert as CEO while teasing a “strategic realignment” that won’t be revealed until early 2024, according to its Q3 report . Design does elaborate on the status of its cash runway, which is projected to keep the lights on “through 2028” as a result of the changes. Shah has chaired the board since 2017 and is connected to two Laura Shawver biotechs as the ex-chairman of Synthorx — purchased by Sanofi — and the current chairman at ARS Pharmaceuticals , which merged with Shawver-led Silverback Therapeutics last year. Siffert took the top spot at Design in October 2020 after resigning as CEO, head of R&D and CMO at Abeona Therapeutics .

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Design Therapeutics, Inc.

Karyopharm Therapeutics, Inc.Nereid AB

[+5]

Indications

Targets

Drugs

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.